Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size

被引:28
作者
Foulon, T
Payen, N
Laporte, F
Bijaoui, S
Dupont, G
Roland, F
Groslambert, P
机构
[1] CHU Grenoble, Dept Biol Integree, Grenoble 09, France
[2] Serv Med Prevent Interuniv Grenoble, F-38400 St Martin Dheres, France
关键词
oral contraceptives; desogestrel; levonorgestrel; serum lipids; HDL subclasses; LDL size;
D O I
10.1016/S0010-7824(01)00224-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This study was designed to determine the effects of two low-dose oral contraceptives, most frequently given in our area, monophasic desogestrel/ethinylestradiol (DG/EE) and triphasic levonorgestrel/ethinylestradiol (LNG/EE), on lipoprotein parameters, especially LDL particle size and HDL subclass distribution (determined by lipid-stained 2%-20% polyacrylamide gradient gel electrophoresis) in 37 healthy normolipidemic women aged 19 to 27 years. Lipid and lipoprotein parameters were measured before the start of treatment and in the third month of oral contraceptive use. Results reflected the estrogen-progestin balance. As compared with baseline values, with both formulations, plasma total cholesterol, phospholipids, and HDL3 cholesterol increased, and LDL-predominant peak size decreased, with a translation of LDL pattern A towards pattern I. With DG/EE, plasma triglycerides, apolipoproteins AI and B increased. With LNG/EE, LDL cholesterol increased, and HDL2 cholesterol decreased. All these modifications were moderate, within threshold limits. Estrogen-dominant monophasic DG/EE appears to be more favorable than progestin-dominant triphasic LNG/EE, since the reduction in LDL-predominant peak size is not associated with an increase in LDL cholesterol or with a decrease in HDL2 cholesterol. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:11 / 16
页数:6
相关论文
共 37 条
[11]   ORAL-CONTRACEPTIVES, LIPIDS AND CARDIOVASCULAR-DISEASE [J].
FOTHERBY, K .
CONTRACEPTION, 1985, 31 (04) :367-394
[12]  
Foulon T, 1999, SCAND J CLIN LAB INV, V59, P239, DOI 10.1080/00365519950185607
[13]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[14]   THE EFFECTS OF DIFFERENT FORMULATIONS OF ORAL-CONTRACEPTIVE AGENTS ON LIPID AND CARBOHYDRATE-METABOLISM [J].
GODSLAND, IF ;
CROOK, D ;
SIMPSON, R ;
PROUDLER, T ;
FELTON, C ;
LEES, B ;
ANYAOKU, V ;
DEVENPORT, M ;
WYNN, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (20) :1375-1381
[15]   RESPONSE OF PLASMA LOW-DENSITY-LIPOPROTEIN SUBFRACTIONS TO ESTROGEN REPLACEMENT THERAPY FOLLOWING SURGICAL MENOPAUSE [J].
GRIFFIN, B ;
FARISH, E ;
WALSH, D ;
BARNES, J ;
CASLAKE, M ;
SHEPHERD, J ;
HART, D .
CLINICAL ENDOCRINOLOGY, 1993, 39 (04) :463-468
[16]   Small low-density lipoprotein particles in women with natural or surgically induced menopause [J].
Ikenoue, N ;
Wakatsuki, A ;
Okatani, Y .
OBSTETRICS AND GYNECOLOGY, 1999, 93 (04) :566-570
[17]   CONTRACEPTIVES CONTAINING DESOGESTREL OR LEVONORGESTREL HAVE DIFFERENT EFFECTS ON SERUM-LIPOPROTEINS AND POSTHEPARIN PLASMA LIPASE ACTIVITIES [J].
KAUPPINENMAKELIN, R ;
KUUSI, T ;
YLIKORKALA, O ;
TIKKANEN, MJ .
CLINICAL ENDOCRINOLOGY, 1992, 36 (02) :203-209
[18]  
Khoo C, 1999, J LIPID RES, V40, P202
[19]   EFFECTS OF 3 COMBINED ORAL-CONTRACEPTIVE PREPARATIONS CONTAINING DESOGESTREL PLUS ETHINYL ESTRADIOL ON LIPID-METABOLISM IN COMPARISON WITH 2 LEVONORGESTREL PREPARATIONS [J].
KLOOSTERBOER, HJ ;
REKERS, H .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (01) :370-373
[20]   EFFECTS OF 2 PROGESTINS WITH DIFFERENT ANDROGENIC PROPERTIES ON HEPATIC ENDOTHELIAL LIPASE AND HIGH-DENSITY LIPOPROTEIN [J].
KUUSI, T ;
NIKKILA, EA ;
TIKKANEN, MJ ;
SIPINEN, S .
ATHEROSCLEROSIS, 1985, 54 (03) :251-262